<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05033990</url>
  </required_header>
  <id_info>
    <org_study_id>21-06023662</org_study_id>
    <secondary_id>R01HL144718</secondary_id>
    <nct_id>NCT05033990</nct_id>
  </id_info>
  <brief_title>SPIROMICS Study of Early COPD Progression (SOURCE)</brief_title>
  <acronym>SOURCE</acronym>
  <official_title>SPIROMICS Study of Early COPD Progression (SOURCE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Weill Medical College of Cornell University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of North Carolina, Chapel Hill</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Jewish Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Illinois at Chicago</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Iowa</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Utah</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wake Forest University Health Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Temple University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>COPD Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Weill Medical College of Cornell University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an observational study of 600 participants to further define the nature of early&#xD;
      chronic obstructive pulmonary disease (COPD) in younger, at-risk individuals.&#xD;
&#xD;
      The study has three main goals:&#xD;
&#xD;
        -  To use CT scan imaging to identify which smokers will develop COPD.&#xD;
&#xD;
        -  To identify biomarkers predictive of smokers that will develop COPD.&#xD;
&#xD;
        -  To determine if sputum (phlegm) can be analyzed to predict which smokers will develop&#xD;
           COPD.&#xD;
&#xD;
      Procedures (methods): All participants will undergo study related questionnaires assessing&#xD;
      medical history, smoke exposure and use, medication use, social and behavioral health,&#xD;
      pulmonary symptoms, food frequency, and will provide nasal swab, blood, stool, and urine&#xD;
      samples, pulmonary function testing to determine function, sputum induction to provide a&#xD;
      sputum sample for airway biospecimen analysis, and CT imaging of the lungs.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 8, 2021</start_date>
  <completion_date type="Anticipated">April 2025</completion_date>
  <primary_completion_date type="Anticipated">January 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>PRM fSAD</measure>
    <time_frame>Year 2-5</time_frame>
    <description>Parametric Response Mapping captures the change in lung density between matched inspiratory and expiratory images thereby enabling the distinction between normal lung parenchyma (PRMNORM), emphysema (PRMEMPH), and non-emphysematous air trapping referred to as functional small airway disease (PRMfSAD).</description>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">600</enrollment>
  <condition>COPD, Early-Onset</condition>
  <arm_group>
    <arm_group_label>Healthy Controls</arm_group_label>
    <description>Participants with no smoking history (&lt; 100 cigarettes in lifetime); post-bronchodilator FEV1/FVC &gt; 0.70; post-bronchodilator FEV1 &gt; 80% predicted; post-bronchodilator FVC &gt; 80% predicted; Chronic Airway Assessment Test (CAAT) score &lt; 10</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gold 0</arm_group_label>
    <description>Participants graded as GOLD 0 by the GOLD grading system: ≥ 10 pack-year smoking history; post-bronchodilator FEV1/FVC &gt; 0.70 and FEV1 &gt; 80% predicted; and Chronic Airway Assessment Test (CAAT) score ≥ 10.&#xD;
GOLD stands for the Global initiative for Chronic Obstructive Lung Disease. The Gold</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Preserved Ratio Impaired Spirometry (PRISm)</arm_group_label>
    <description>Participants with with ≥ 10 pack-year smoking history; post-bronchodilator FEV1/FVC &gt; 0.70 and FEV1 &lt; 80% predicted.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gold 1 - 2</arm_group_label>
    <description>Participants graded as GOLD 0 by the GOLD grading system: ≥ 10 pack-year smoking history; post-bronchodilator FEV1/FVC &lt; 0.70 and FEV1 50-80% predicted.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Plasma, serum, RNA, DNA, exhaled breath condensate, nasal swab, sputum, urine, and stool&#xD;
      samples will be collected.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        12 clinical centers across the US will enroll a total of 600 participants, 30-55 years old,&#xD;
        both sexes, all races, and all ethnicities. The participants will include never-smokers&#xD;
        (n=20) and GOLD stage 0-2 participants (n=580).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  20 of the 600 will be healthy controls: ages 30-55 years; with no smoking history (&lt;&#xD;
             100 cigarettes in lifetime), including vaping and cannabis use; post-bronchodilator&#xD;
             forced expiratory volume in 1 second (FEV1)/forced vital capacity (FVC) &gt; 0.70;&#xD;
             post-bronchodilator FEV1 &gt; 80% predicted; post-bronchodilator FVC &gt; 80% predicted;&#xD;
             Chronic Airway Assessment Test (CAAT) score &lt; 10; and willingness to also participate&#xD;
             in the bronchoscopy sub-study.&#xD;
&#xD;
          -  Approximately one-third of the 580 will be GOLD 0 participants: ages 30-55 years; with&#xD;
             ≥ 10 pack-year smoking history; post-bronchodilator FEV1/FVC &gt; 0.70 and FEV1 &gt; 80%&#xD;
             predicted; and Chronic Airway Assessment Test (CAAT) score ≥ 10. This early COPD group&#xD;
             has been chosen because it is not currently well-represented in COPDGene and SPIROMICS&#xD;
             cohorts.&#xD;
&#xD;
          -  Approximately one-third of the 580 will be Preserved Ratio Impaired Spirometry (PRISm)&#xD;
             participants: ages 30-55 years; with ≥ 10 pack-year smoking history;&#xD;
             post-bronchodilator FEV1/FVC &gt; 0.70 and FEV1 &lt; 80% predicted. This early COPD group&#xD;
             was enrolled in small numbers in the COPDGene study, but was excluded from SPIROMICS.&#xD;
&#xD;
          -  Approximately one-third of the 580 will be GOLD 1-2 participants: ages 30-55 years;&#xD;
             with ≥ 10 pack-year smoking history; post-bronchodilator FEV1/FVC &lt; 0.70 and FEV1&#xD;
             50-80% predicted. This early COPD group has been chosen because it is also not&#xD;
             currently well-represented in the first funded phase of the COPDGene and SPIROMICS&#xD;
             cohorts.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Severe asthma, which is defined as any of the following:&#xD;
&#xD;
               -  Current (i.e., at the time of the visit) Global Initiative for Asthma (GINA) Step&#xD;
                  4 or higher therapy (medium dose inhaled corticosteroids (ICS)/long-acting beta&#xD;
                  agonist (LABA) or high dose ICS or add-on long-acting muscarinic agonist (LAMA);&#xD;
                  Medium dose &gt; 250 fluticasone propionate, = 100 fluticasone furoate, &gt; 200&#xD;
                  beclomethasone, &gt; 400 budesonide, &gt; 220 mometasone). We will accept low-dose&#xD;
                  ICS/LABA or medium dose ICS; or&#xD;
&#xD;
               -  Three or more unscheduled healthcare visits (provider/urgent care/ER) for asthma&#xD;
                  in the past 12 months; or&#xD;
&#xD;
               -  One asthma hospitalization in the past 12 months.&#xD;
&#xD;
          -  Concurrent participation in a therapeutic trial where treatment is blinded.&#xD;
&#xD;
          -  Active pregnancy at the time of the baseline visit or planning to become pregnant&#xD;
             during the course of the study. This special population is being excluded to minimize&#xD;
             potential for fetal radiation exposure.&#xD;
&#xD;
          -  Cognitive dysfunction that prevents the participant from completing study procedures.&#xD;
&#xD;
          -  BMI &gt; 35.0 kg/m^2 at baseline, due to the effects of body weight on CT scan imaging&#xD;
             quality.&#xD;
&#xD;
          -  The presence of a respiratory condition other than COPD or asthma, or of a comorbid&#xD;
             condition that in the judgment of the investigator may be the principal cause of&#xD;
             respiratory symptoms (e.g., dyspnea or decreased exercise tolerance).&#xD;
&#xD;
          -  Any illness expected to cause mortality in the next three years.&#xD;
&#xD;
          -  Any implanted metallic devices or prosthesis above the waist that could degrade&#xD;
             thoracic CT scan image quality.&#xD;
&#xD;
          -  History of thoracic radiation or thoracic surgery with resection of lung tissue.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fernando J Martinez, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Weill Medical College at Cornell University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>MeiLan K Han, MD,MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jeffrey L Curtis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lori A Bateman, MS</last_name>
    <phone>9199623266</phone>
    <email>lbateman@email.unc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>David Couper, PhD</last_name>
    <phone>9199623229</phone>
    <email>david_couper@unc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Dransfield, MD</last_name>
      <email>mdransfield@uabmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Sonya Hardy</last_name>
      <phone>(205) 966-6601</phone>
      <email>sonyahardy@uabmc.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of California Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Igor Barjaktarevic, MD, PhD</last_name>
    </contact>
    <contact_backup>
      <last_name>Roslynn Marzan-McGill, CPT, CCRP</last_name>
      <phone>(310) 825-2616</phone>
      <email>rmcgill@mednet.ucla.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>National Jewish Health</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80206</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Russell Bowler, MD, PhD</last_name>
    </contact>
    <contact_backup>
      <last_name>Alex Johnson, MSW</last_name>
      <phone>(303) 398-1943</phone>
      <email>jonesa@njhealth.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Illinois Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60608</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jerry Krishnan, MD, PhD</last_name>
    </contact>
    <contact_backup>
      <last_name>Julie Delisa</last_name>
      <phone>(855) 494-3393</phone>
      <email>breathe@uic.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alejandro Comellas, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Mike Wurth</last_name>
      <phone>(319) 356-1785</phone>
      <email>mike-wurth@uiowa.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Bayview Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nadia Hansel, MD, MPH</last_name>
    </contact>
    <contact_backup>
      <last_name>Cheryl Clare</last_name>
      <phone>(410) 550-2864</phone>
      <email>Cdaniel9@jhu.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48130</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Meilan Han, MD, MPH</last_name>
      <email>mrking@med.umich.edu</email>
    </contact>
    <contact_backup>
      <last_name>Crystal Cutlip</last_name>
      <phone>(734) 647-6399</phone>
      <email>ccutlip@med.umich.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>R. Graham Barr, MD, PhD</last_name>
    </contact>
    <contact_backup>
      <last_name>Michael Sheffey</last_name>
      <phone>(347) 835- 8180</phone>
      <email>ms5394@cumc.columbia.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Wake Forest</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stephen Peters, MD, PhD</last_name>
    </contact>
    <contact_backup>
      <last_name>Marissa Millard</last_name>
      <phone>(336) 713-9190</phone>
      <email>mmillard@wakehealth.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Temple University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>10140</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gerald Criner, MD, FACP</last_name>
    </contact>
    <contact_backup>
      <last_name>Keith Johnson</last_name>
      <phone>(215) 707-4547</phone>
      <email>keith.johnson@tuhs.temple.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Paine Robert, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Martin Villegas</last_name>
      <phone>(801) 581-6496</phone>
      <email>mvillegas@hsc.utah.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 26, 2021</study_first_submitted>
  <study_first_submitted_qc>September 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 5, 2021</study_first_posted>
  <last_update_submitted>October 7, 2021</last_update_submitted>
  <last_update_submitted_qc>October 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease Progression</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

